We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Ultra-Fast Test Screens for All Types of Cancer with Simple Blood Draw

By LabMedica International staff writers
Posted on 29 Aug 2024
Print article
Image: The Rapid Cancer Screening Test delivers results in just 2 hours, compared to the 2-3 weeks typical with other tests (Photo courtesy of Shutterstock)
Image: The Rapid Cancer Screening Test delivers results in just 2 hours, compared to the 2-3 weeks typical with other tests (Photo courtesy of Shutterstock)

Cancer can occur at any stage of life, irrespective of age, lifestyle, or genetic background, making early detection critical for effective treatment and better patient outcomes. This underscores a pressing need for improved diagnostic methods in the medical field. Current cancer detection methods face challenges such as limited availability of screening tests, lengthy result processing times, high costs, and invasive procedures. Now, a pioneering technology has been developed that facilitates the early detection of cancer, potentially as early as stage -1, and aids in guiding subsequent imaging tests.

Oncosure (Pompano Beach, FL, USA) has launched its innovative Rapid Cancer Screening Test, democratizing access to early cancer detection. This test, requiring only a single blood draw, is capable of screening for all cancer types, thereby providing reassurance to individuals. Oncosure's cutting-edge screening technology employs rapid in situ hybridization and DNA fluorescent probes to deliver comprehensive and accurate cancer screening. The technology combines a rapid SITU hybridization platform, DNA fluorescent probes for ploidy detection, and cost-effective density gradient and low sequential centrifugation methods to provide thorough screening for aneuploidy across all chromosomes.

The Oncosure test identifies oncosomes—tiny vesicles that are markers of cancer cells—across all types of cancer. Employing advanced fluorescent microscopy, the test ensures precise and actionable outcomes. It offers a swift and dependable method for detecting cancer at very early stages, even stage -1, providing results that are both fast and definitive within a few hours. This enables healthcare providers to make timely decisions. Additionally, the Oncosure test can be instrumental in monitoring the efficacy of ongoing cancer treatments and in providing early detection of cancer recurrence for those in remission, enhancing the chances for successful intervention.

"One blood draw, all cancers—this is the future of cancer screening," said Jason Andrews, Vice President of Oncosure. "Cancer doesn't wait for symptoms, and neither should you. Our test empowers everyone to screen for any type of cancer with a single, non-invasive test."

Related Links:
Oncosure

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.